Welcome to our dedicated page for BOUNDLESS BIO SEC filings (Ticker: BOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles SEC filings for Boundless Bio, Inc. (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology and ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers. The filings provide official details on the company’s financial condition, governance, and key corporate events.
Among the documents available are Current Reports on Form 8-K. For example, Boundless Bio filed 8-Ks dated August 5, 2025, and November 5, 2025, each noting that the company issued press releases announcing financial results for the quarters ended June 30, 2025, and September 30, 2025, respectively. These 8-Ks explain that the earnings press releases are furnished as exhibits and describe how they are treated under Section 18 of the Securities Exchange Act of 1934.
An additional Form 8-K dated June 23, 2025, reports the results of the company’s annual meeting of stockholders. This filing summarizes stockholder votes on the election of Class I directors to serve until the 2028 annual meeting of stockholders and on the ratification of KPMG LLP as Boundless Bio’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Vote totals for each proposal are presented in tabular form within the filing.
In its press releases, Boundless Bio also directs readers to annual and quarterly reports, such as its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarter ended September 30, 2025, for detailed risk factor discussions and additional financial and operational information. Those filings, together with 8-Ks, form the core of the company’s SEC disclosure record.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand items such as earnings announcements, stockholder vote outcomes, and updates referenced in 8-Ks. Real-time integration with the SEC’s EDGAR system means new BOLD filings appear promptly, while structured views make it easier to locate specific forms, including 8-Ks related to financial results and governance matters. This allows users to review Boundless Bio’s regulatory history and disclosures that frame the development of its ecDTx pipeline and clinical programs.
Boundless Bio, Inc. is a clinical-stage oncology company focused on cancers driven by extrachromosomal DNA (ecDNA), which it estimates occur in 14–17% of patients and are linked to poor survival and resistance to current therapies. Using its Spyglass discovery platform, the company designs small-molecule ecDNA-directed therapeutic candidates (ecDTx) that aim to exploit synthetic lethal vulnerabilities in ecDNA-positive tumors.
Lead candidate BBI-940, an oral degrader of a kinesin involved in DNA segregation, entered a Phase 1 first-in-human trial (KOMODO‑1) in February 2026 in ER+/HER2‑ metastatic breast cancer and TNBC‑LAR, with initial proof-of-concept data expected within the current cash runway. Boundless has discontinued development of CHK1 inhibitor BBI‑355 and RNR inhibitor BBI‑825 after a strategic portfolio review to prioritize BBI‑940. The company reports a limited operating history, expects significant losses for the foreseeable future, requires substantial additional capital, and highlights numerous clinical, regulatory, competitive, and listing risks. The aggregate market value of non‑affiliate common stock was approximately $18.0 million based on a $1.01 share price, and 22,407,251 common shares were outstanding as of March 2, 2026.
Boundless Bio, Inc. reported a full-year 2025 net loss of
The FDA accepted the Investigational New Drug application for BBI-940, and the first-in-human KOMODO-1 study in difficult-to-treat breast cancers is open for enrollment. Boundless plans to cease enrollment in the POTENTIATE trial combining BBI-355 and BBI-825 to prioritize BBI-940. Effective March 3, 2026, director Christine Brennan, Ph.D. resigned from the board in connection with a new role at Johnson & Johnson Development Corporation, and her departure was not due to any disagreement with the company.
Boundless Bio, Inc. (BOLD) received an amended Schedule 13G/A indicating that former reporting holders now report zero ownership of its common stock as of December 31, 2025. Nextech VI Oncology SCSp, Nextech VI GP S.a. r.l., Ian Charoub, Costas Constantinides and Rocco Sgobbo each report beneficial ownership of 0 shares, representing 0.0% of the common stock.
The filers state that they own 5 percent or less of the class and certify that the securities referenced were not acquired and are not held for the purpose of changing or influencing control of Boundless Bio, and are not held in connection with any control-related transaction.
FMR LLC and Abigail P. Johnson filed an amended Schedule 13G reporting beneficial ownership of 2,684,022 shares of Boundless Bio Inc. common stock, representing 12.0% of the class as of 12/31/2025. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
The interest of Fidelity Growth Company Commingled Pool in Boundless Bio’s common stock amounted to 1,237,265 shares, or 5.5% of the outstanding common stock as of 12/31/2025.
Boundless Bio, Inc. granted a stock option to Chief Legal Officer and Corporate Secretary Jessica Oien. The option covers 220,000 shares of common stock at an exercise price of $1.26 per share.
The option was awarded on January 23, 2026 and expires on January 22, 2036. Vesting starts on January 1, 2026 and occurs in 48 substantially equal monthly installments, so 1/48th of the option vests on February 1, 2026 and monthly thereafter, aligning the award with long-term service at the company.
Boundless Bio, Inc. granted Chief Scientific Officer Christian Hassig a stock option covering 230,000 shares of common stock on January 23, 2026. The option has an exercise price of $1.26 per share and was received at no cost on the grant date. It is held directly by the reporting person.
The vesting start date is January 1, 2026. The option vests in 48 substantially equal monthly installments, with 1/48 of the award vesting on February 1, 2026 and additional 1/48 portions vesting each month thereafter until fully vested.
Boundless Bio, Inc. Chief Medical Officer Robert Doebele reported receiving a stock option award on January 23, 2026. The option covers 230,000 shares of Boundless Bio common stock at an exercise price of $1.26 per share, held directly.
The vesting commencement date is January 1, 2026. The option vests in 48 substantially equal monthly installments, so 1/48th of the award vests on February 1, 2026 and then monthly thereafter until fully vested. Following this grant, Doebele beneficially owns 230,000 derivative securities in the form of stock options.
Boundless Bio, Inc. reported that its President and CEO, Zachary Hornby, received a grant of a stock option covering 600,000 shares of common stock. The option has an exercise price of $1.26 per share and was granted on January 23, 2026.
The option begins vesting from a commencement date of January 1, 2026, in 48 substantially equal monthly installments. As a result, 1/48th of the option vests on February 1, 2026, with additional monthly vesting thereafter until fully vested, and it is scheduled to expire on January 22, 2036.
Boundless Bio, Inc. reported that officer David A. Hinkle received a new stock option award. On January 23, 2026, he was granted an option to purchase 140,000 shares of common stock at an exercise price of $1.26 per share.
The option’s vesting start date is January 1, 2026. It vests in 48 substantially equal monthly installments, so 1/48 of the option vests on February 1, 2026 and then continues to vest monthly until fully vested on the fourth anniversary, assuming continued service.
Boundless Bio (Nasdaq: BOLD) filed its Q3 report and posted a net loss of $13.9 million. Operating expenses were $15.1 million, driven by research and development of $10.7 million and general and administrative of $4.5 million. Interest income was $1.3 million.
Liquidity remained solid with $117.6 million in cash, cash equivalents, and short‑term investments as of September 30, 2025. Management states this supports operations into the first half of 2028. The company has an at‑the‑market equity program of up to $14.5 million; no shares were sold under the program as of September 30, 2025.
Pipeline updates center on the POTENTIATE study: the BBI‑355 (CHK1 inhibitor) and BBI‑825 (RNR inhibitor) combination arm opened for enrollment in Q3 2025. Earlier monotherapy and third‑party combo arms of BBI‑355 were wound down in May 2025 as part of a portfolio prioritization and cost streamlining. Beyond the lead program, the company selected BBI‑940 (Kinesin degrader) as a development candidate and expects to submit an IND and start first‑in‑human testing in the first half of 2026. Shares outstanding were 22,385,611 as of October 31, 2025.